reports
DGAP-News: Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug ...
DGAP-News: Tetra Bio-Pharma Inc. / Key word(s): Miscellaneous Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF(TM) from the European Medicines Agency 21.10.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Ottawa, October 21, 2021 (CNW) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") () () (), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company's a...
DGAP-News: Tetra Bio-Pharma Provides Update on Clinical Development Pr...
DGAP-News: Tetra Bio-Pharma Inc. / Key word(s): Miscellaneous Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF(TM) 14.10.2021 / 14:39 The issuer is solely responsible for the content of this announcement. Ottawa, October 14, 2021 (CNW) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") () () (), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF(TM). QIXLEEF(TM) is a botanical inhaled drug product with a fixed ratio of ...
Tetra Bio-Pharma annonce la taille du placement négocié entre deux s...
Tetra Bio-Pharma annonce la taille du placement négocié entre deux séances boursières /NE PAS DISTRIBUER À DES AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS/ OTTAWA, 15 mai 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (« Tetra » ou la « Société ») (TSX-V: TBP) (OTCQB: TBPMF) est heureuse d'annoncer que dans le cadre du placement négocié entre deux séances boursières préalablement annoncé, un syndicat de placeurs pour compte dirigé par Raymond James Ltée. et Canaccord Genuity Corp. (ensemble, les « placeurs pour compte »), ont convenu d'acheter 33,089,000 unités (les « ...
Tetra Bio-Pharma Announces Sizing of Public Offering
Tetra Bio-Pharma Announces Sizing of Public Offering NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES OTTAWA, May 15, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), is pleased to announce that, in connection with its previously announced overnight marketed offering, a syndicate of agents led by Raymond James Ltd. and Canaccord Genuity Corp. (collectively, the "Agents"), have agreed to sell 33,089,000 units ("Units") of the Company at a price of $0.26 per Unit (the "Issue Price") for aggregate gross proceeds...
Tetra Bio-Pharma annonce un placement négocié entre deux séances bo...
Tetra Bio-Pharma annonce un placement négocié entre deux séances boursières NE PAS DISTRIBUER À DES AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS OTTAWA, 14 mai 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (« Tetra » ou la « Société ») (TSX-V: TBP) (OTCQB: TBPMF), un leader dans la recherche sur des médicaments à base de cannabinoïdes, est heureuse d'annoncer qu'elle procédera à un placement d'unités (les « unités ») de la Société négocié entre deux séances boursières (le « placement »). Chaque unité est offerte à un prix 0,26 $ CA par unité (le « prix d'émission ») et...
Tetra Bio-Pharma Announces Overnight Marketed Offering
Tetra Bio-Pharma Announces Overnight Marketed Offering NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES OTTAWA, May 14, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it has commenced an overnight marketed public offering (the “Offering”) of units (the “Units”) of the Company. Each Unit is offered at a price of $0.26 per Unit (the “Issue Price”) with each Unit consisting of one common share in the capital of Tetra (a “Comm...
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011 FDA Grants Type B meeting to discuss Tetra’s HCC011 with Orphan Drug Designation OTTAWA, April 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the U.S. Food & Drug Administration ("FDA") has granted the Company’s request for a Type B meeting related to its proposed clinical program and overall premarketing requirements for the Company’s product HCC011 with Orphan Drug De...
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following ...
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to determine the levels of cannabinoid metabolites (e.g., 7-COOH-CBD), cannabin...
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and...
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A OTTAWA, March 30, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX-V: TBP) (OTCQB: TBPMF), announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 ("Restated MD&A"), which is available on SEDAR under the Corporation's profile. The board of directors of the Corporation, based on the recommendation of the audit committee in consultation with the management of the Corporation, has determined that the Co...
Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinic...
Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial Survey respondents are Patients and Physicians from the US and Canada OTTAWA, March 26, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the results of a survey conducted among US and Canadian patients and physicians which validated the primary endpoint of the SERENITY© pivotal trial. The results confirm that the primary endpoint in the SERENITY© clinical trial is accurate About ...
Tetra Bio-Pharma Provides Management Update on COVID-19
Tetra Bio-Pharma Provides Management Update on COVID-19 OTTAWA, March 23, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today would like to announce that it has ensured that all of its employees work under conditions that comply with federal and provincial public health recommendations. Additionally, following the completion of its $17.8 M financing in February and early March, the Company is in a good position to maintain its drug development programs. Regulatory activi...
Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and pu...
Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm OTTAWA, March 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged Alpha Bronze LLC., by its principal, Mr. Pascal Nigen, an investor relations, management consulting and financial communications firm to implement and execute a comprehensive investor relations and communications program. “I am very pleased and excited to have engaged Alpha B...
Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientif...
Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific Co-Development will provide pipeline for next generation pharmacology research of Rx drugs to further secure growth for Tetra Bio-Pharma Inc OTTAWA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agoni...
Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Ty...
Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA CAUMZ targeting survival indications in advanced incurable cancer. Eligible for Fast Track designation and Accelerated Approval regulatory program.505(b)(2) NDA pathway provides significant cost savings. OTTAWA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for CAUMZ™ following the previ...
Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following ...
Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA QIXLEEF global market is expanded to include noncancer pain indications.Scientific approach to quality control of QIXLEEF validated by FDA. OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for QIXLEEF™ following the previously announced Letter of Advice and Type B...
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its O...
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting Trial expected to be completed by April 30, 2020 OTTAWA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced the initiation of its clinical trial for its synthetic cannabinoid therapy (PPP003v) for the treatment of ophthalmic eye pain in the veterinary settin...
Tetra Bio-Pharma Appoints Sylvain Chrétien as President
Tetra Bio-Pharma Appoints Sylvain Chrétien as President Seasoned executive brings 31 years of experience leading commercial and business operations of growth-oriented global biopharmaceutical businesses OTTAWA, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB: TBPMF) a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Sylvain Chrétien as President of Tetra Bio-Pharma Inc. Mr. Chrétien will report directly to Guy Chamberland, CEO of Tetra. Mr. Chamberland was instrumental in select...
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints L...
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011 Agreement secures a 2D patented printing technology that will significantly boost production capacity and reduce production costs Further protects CAUMZ™ and HCC011 with four additional manufacturing patents OTTAWA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has signed a definitive manufacturing agreement with Vitiprints LLC, for the commercial s...
Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clini...
Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003 Tetra’s sterile cannabinoid manufacturing facility fully validated and operationalTetra’s subsidiary, Panag Pharma, ready to initiate the treatment phase of clinical trial of PPP003 for treatment of eye pain OTTAWA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide an update on its veterinary clinical trial to evaluate the safety, tolerability and potent...
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its...
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs Tetra to partner with a Contract Sales Organization (CSO) for both TERPACAN™ and AWAYE™ Tetra expanding sales partnership agreements to the Middle East OTTAWA, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today provided an update on its commercialization initiatives to bring its OTC Drug Identification Number (DIN) products and natural health products to market in 2020. Following the receipt of two...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.